MSN Home  |  My MSN  |  Hotmail
Sign in to Windows Live ID Web Search:   
go to MSNGroups 
Groups Home  |  My Groups  |  Language  |  Help  
 
Fight for a FutureFightforaFuture@groups.msn.com 
  
What's New
  Join Now
  HOME FFF  
  Research Project  
  Reports  
  Messageboard  
  News research  
  Supplements  
  Creatine  
  Steroids  
  Physical Therapy  
  Orthopaedic  
  Anesthesia in DMD  
  Osteoporosis  
  Important info  
  Teacher Info  
  Alternative Therapy  
  Inspirational stories  
  Links  
  Pictures  
  Contact us  
  About us  
  Calendar  
  
  
  Tools  
 

 

NEWS RESEARCH


 

Latest updates in research:

http://www.distrofiamuscular.net/news.htm


NEWS:

5 June, 2003 Trial in France.

http://groups.msn.com/FightforaFuture/newinresearch.msnw?action=get_message&mview=0&ID_Message=523&LastModified=4675424915932533659


Biochem Biophys Res Commun 2003 Feb 28;302(1):109-13

Pentoxifylline protects L929 fibroblasts from TNF-alpha toxicity via the induction of heme oxygenase-1.

Oh GS, Pae HO, Moon MK, Choi BM, Yun YG, Rim JS, Chung HT.

Medicinal Resources Research Center (MRRC), Wonkwang University, Iksan, 570-749, Chonbuk, Republic of Korea

Tumor necrosis factor-alpha (TNF-alpha) is recognized as a principal mediator of a variety of inflammatory conditions. Pentoxifylline (PTX), which can inhibit cellular TNF-alpha synthesis, also attenuates the toxic effect of TNF-alpha. However, the mechanism underlying PTX-induced cytoprotection is unknown. Heme oxygenase 1 (HO-1) is an enzyme which degrades heme into biliverdin, free iron, and carbon monoxide (CO). This enzyme has recently been shown to have anti-inflammatory and cytoprotective effects. In this study, we investigated whether protection by PTX against TNF-alpha-mediated toxicity could be related to its ability to induce HO-1 expression and HO activity in L929 cells. PTX in the range of 0.1-1.0mM significantly induced HO-1 expression and the resulting HO activity. Pre-incubation of L929 cells with either PTX or the HO activator hemin resulted in the protection of the cells against TNF-alpha-mediated toxicity. Zinc protoporphyrin, a specific HO competitive inhibitor, abrogated the protective effect of PTX. Hemoglobin, a scavenger of CO, reversed the protective effect of PTX. A cytoprotection comparable to PTX was observed when the cells were treated with the CO-releasing compound tricarbonyldichlororuthenium(II) dimer. These results suggest that HO-1 expression and the ensuing formation of the HO metabolite CO may be a novel pathway by which PTX protects L929 cells from TNF-alpha-mediated toxicity.


Novel muscle-derived stem cells deliver dystrophin into a dystrophin-deficient murine heart


NEW LEAD FOR ARTHRITIS DRUGS

New lead for arthritis drugs
Scientists find switch that sends white cells rushing to cause inflammation.
7 March 2003

JOHN WHITFIELD

Researchers have found a molecular switch that enables the immune system's cells to function without oxygen. Jamming the switch stops inflammation, suggesting a new way to treat arthritis and other diseases in which the body turns on itself.

The switch is in white blood cells, the immune system's special forces. These cells rush into ailing tissues, and form the first line of defence against incoming infection, eating invading bacteria. This influx is one of the causes of inflammation.

Randall Johnson of the University of California, San Diego, and his colleagues have found that a molecule called HIF-1 alters white blood cells so that they can survive without oxygen1  - a trick that is essential to their defensive role, as damaged tissues are often low in the gas.

The team genetically engineered mice to lack HIF-1 in their white blood cells. The modified cells stay away from low-oxygen environments, and destroy few bacteria. "It's as if they can't manage the energetic burst needed to kill bacteria," says Johnson.

The animals' skin does not redden in response to irritating chemicals, and their joints do not develop arthritis when injected with a substance that normally causes swelling.

"This is a very important observation in terms of understanding the biology of inflammation," says cancer biologist Adrian Harris of the University of Oxford, UK.

HIF-1 was known to switch on genes that trigger the production of red blood cells or the growth of blood vessels. "Tying HIF-1 to the biology of white blood cells is a big contribution," says blood specialist Franklin Bunn of Harvard Medical School, Massachusetts.

Cancer researchers are already looking for drugs that block HIF-1 - which they hope will starve tumours of oxygen. Such drugs might also help to treat arthritis, says Johnson.

But without HIF-1, a mouse's immune system is also much weaker. The molecule's many jobs will make it difficult to disable without adverse side-effects. Bunn warns: "You're going to have to work very hard to find a targeted drug."

 

References

Cramer, T. et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell, 112, 645 - 657, (2003). |Homepage|


Curr Opin Clin Nutr Metab Care 2003 Jan;6(1):87-93

Exercise treatment to counteract protein wasting of chronic diseases.

Zinna EM, Yarasheski KE.

PURPOSE OF REVIEW The objective is to summarize the findings from recent (June 2001-2002) studies that have examined the potential benefits of exercise training for the treatment of wasting associated with sarcopenia, cancer, chronic renal insufficiency, rheumatoid arthritis, osteoarthritis and HIV. In many clinical conditions, protein wasting and unintentional weight loss are predictors of morbidity and mortality. The pathogenesis of protein wasting in these conditions can be different, but the fundamental mechanism is an imbalance between muscle protein synthetic and proteolytic processes. The muscle proteins most affected and the precise alterations in their synthetic and proteolytic rates that occur in each cachectic condition are still under investigation. RECENT FINDINGS Regular exercise, or sometimes just a modest increase in physical activity, can mitigate muscle protein wasting. Aerobic exercise training primarily alters mitochondrial and cytosolic proteins (enzyme activities), while progressive resistance exercise training predominantly increases contractile protein mass. Previous studies indicate that resistance exercise acutely increases the muscle protein synthetic rate more than muscle proteolysis such that the muscle amino acid balance is increased for up to 2 days after exercise. Progressive resistance exercise training increases muscle protein synthesis and muscle mass, but attenuates the increment in proteolysis that results from a single bout of resistance exercise. The cellular mechanisms that produce these adaptations are not entirely clear.SUMMARY In general, patients with wasting conditions who can and will comply with a proper exercise program gain muscle protein mass, strength and endurance, and, in some cases, are more capable of performing the activities of daily living.

Notice: Microsoft has no responsibility for the content featured in this group. Click here for more info.
  Try MSN Internet Software for FREE!
    MSN Home  |  My MSN  |  Hotmail  |  Search
Feedback  |  Help  
  ©2005 Microsoft Corporation. All rights reserved.  Legal  Advertise  MSN Privacy